A review : Cell Penetrating Peptides - An advanced drug delivery system & therapeutic approach for the treatment of Cancer

By

Jarin Tasnim
ID:20146020

A thesis submitted to the School of Pharmacy in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy (B.Pharm)

School of Pharmacy
Brac University
October 2024

Declaration

It is hereby declared that

1. The thesis submitted is my/our own original work while completing degree at Brac University.

2. The thesis does not contain material previously published or written by a third party, except where this is appropriately cited through full and accurate referencing.

3. The thesis does not contain material which has been accepted, or submitted, for any other degree or diploma at a university or other institution.

4. I/We have acknowledged all main sources of help.

Student's Full Name & Signature:

Jarin Tasnim
ID- 20146020

Approval

The thesis titled “A review : Cell Penetrating Peptides - An advanced Drug delivery system and Therapeutic approach for the treatment of Cancer ” submitted by Jarin Tasnim- ID : 20146020, of Summer 2023 has been accepted as satisfactory in partial fulfillment of the requirement for the degree

of Bachelor of Pharmacy.

Supervised By:

Sabrina Sharmin, Phd
Assistant Professor
School of Pharmacy
Brac University

Approved By:

Dean :

A.F.M. Yusuf Haider, PhD
Acting Dean, School of Pharmacy
Professor, Department of Mathematics
and Natural Sciences
Brac University

Ethics Statement

This project does not involve any kind of animal and human trial.

Abstract :

In recent years, medical science has acheived a lot of success in the field of treatment .Treating cancer sucessfully is one of them. But though having unimaginable success and advancement in the medical field the rate of death due to cancer is increasing day by day with a growing population. According to the World Health Organization there were abouth estimated 20 million new cancer cases and 9.7 million deaths in 2022. So it is very clear that conventional chemotherapy or cancer treatment requires more advanced aproaches in order to control this growing death rate due to cancer. Application of Cell Penetrating Petides is one of those approaches . One extremely promising method for intracellular medication delivery is the use of cell-penetrating peptides. Cancer therapy is a pertinent clinical use of cell-penetrating peptides. Both oligonucleotide-based treatments and traditional small-molecule medications might be more effectively treated by increasing their absorption in tumor cells using peptide-based delivery.The cancer applications of cell penetrating peptides as delivery systems are the main focus of this review;including various aspects of drug loading, cargoes, and delivery are covered along with techniques for targeted delivery, transducible agents coupled to cell-penetrating peptides, and activatable cell-penetrating peptide. Clinical limitations with strategies to overcome those and comparison with conventional treatment are also two important aspects of this review.

Key words : Cell penetrating peptides , Chemotherapy , Doxorubicin , Paclitaxel , activatable peptides , cargoes , drug loading ,drug delivery

Table of Contents : **Page no :**

List of table :

List of figures :

List of Acronyms :

CPPs - Cell Penetrating Peptides

DOX - Doxurubicin

PTX - Paclitaxel

TAM - Tamoxifen

BBB- Blood brain barrier

ACP- Anticancer peptides

ACPPs - Activatable Peptides

SCLC - Small cell Lung Cancer

Chapter 01

Introduction

In 2020, cancer ranked as the primary cause of death globally, taking around 10 million lives. Men made up 9.3 million and women made up 8.8 million of these instances. The most prevalent malignancies globally in 2020 were lung and breast cancers, which accounted for 12.2% and 12.5% of all newly diagnosed cases, respectively.In 2020, cancer of colorectal accounted for 10.7% of all new cases and was the third most frequent cancer with 1.9 million new cases. As the most frequent cancer among males globally, lung cancer accounted for 15.4% of all newly diagnosed cases in 2020.With the exception of non-melanoma skin cancer, the top three cancers—lung, prostate, and colorectal—accounted for 41.9% of all cancer cases.The stomach and liver were two more prevalent malignancies that contributed more than 5%. In 2020, breast cancer was responsible for 25.8% of all newly diagnosed instances of cancer in women globally, making it the most frequent disease among them. Breast, colorectal, and lung—accounted for 44.5% of all cancer cases.Cervical cancer, frequently referred to as cancer of the cervix uteri, is fourth among cancers that affect women and seventh among all cancers,there were about 604,000 new cases of cervical cancer [40]. A particularly appealing method for intracellular medication delivery is offered by cell-penetrating peptides. Cancer treatments tend to be one important clinical use for cell-penetrating peptides. Drug delivery based on peptides has the potentiality to improve the effectiveness of oligonucleotide- or traditional small-molecule-based therapies via accelerating drug absorption in tumor cells. Over the last decade, the discovery of several CPPs has revealed the intriguing possibility of peptides for drug transport into cells. Several CPP-conjugated therapies (CTTs) have been utilized to improve the extracellular and intracellular uptake of molecules of small size and biological molecules that includes plasmid DNA, siRNA, oligonucleotides, and peptide nucleic acid (PNA).These therapies show great potential for therapeutic success in treating cancer**.** Whereas cancer has been acknowledged as a human illness for thousands of years, medical research has recently come to a clear understanding of the nature and progression of the disease. More cancer patients are surviving longer nowadays. Nonetheless, treating some disease types continues to be excruciatingly challenging. Modern medical care may increase survival rates and 15 greatly enhance quality of life. Cell-penetrating peptides might dramatically enhance cancer diagnosis, prevention, and treatment.[37]

1.1 : Cancer

Cancer is a condition in which cells produce uncontrolled and spread throughout the body. Cancer may develop practically anywhere in the person's body, and which contains billions of cells. Cancerous tumors expand into or invade neighboring tissues, and they can migrate to distant locations in the body to create more tumors, which is known as metastasis. Cancerous tumours are also known as tumors which are malignant. Many cancers develop into solid tumors, while blood cancers, such as leukemias, do not.The most frequent cancers include carcinoma of the breast, cancer of the prostate, lung and bronchus cancer, colon and cancer of the rectal area, melanoma of the skin, cancers of the bladder, kidney and pelvic renal cancer, non-Hodgkin lymphoma, cancers of the endometrium, cancer of the pancreas leukemia, a cancer of the thyroid, and the cancer of the liver[41] . Owing to several misconceptions and superstitions, cancer is referred to as "the deity of all a state of terror. One of the main characteristics of cancer is the fast growth of aberrant cells that can infect nearby body parts and spread to other organs. These cells can expand beyond their normal boundaries. According to estimates, cancer accounts for one in six deaths worldwide[2]. When one or more genes alter and produce malignant cells, cancer begins. Tumors, or cancer clusters, are produced by these cells. Cancerous cells have the ability to separate from tumors and spread throughout your body through the lymphatic or circulatory systems.Cancer is a hereditary illness. It occurs when genes controlling cell activity change, producing aberrant cells that proliferate and divide until they finally interfere with normal bodily functions**.** WHO depictions show that fatalities from cancer outnumber those from coronary heart disease. Over the coming decades, there will likely be a rise in the cancer burden due to these worldwide demographic and epidemiologic shifts, mostly in low- and middle-income nations. By 2025, it is anticipated that there will be more than 20 million documented instances of cancer yearly[30]. The conceptual framework that cancer is "a disease of the genes" was formerly known as held about knowledge. Under this approach, mutations are considered primarily as static causes and, to a certain extent, as manifestations of preference factors operating in a population and environment that are changing constantly.Cancer is a state caused by altered cells proliferating out of control while being susceptible to biological selection-driven evolution. According to Rudolf Virchow's "cellular theory" of disease, which dates back to the middle of the 19th century, alterations in cells are the source of all illnesses, including cancer.An key realization in the middle of the 20th century was that normal cells are the source of cancer cells.

Following developments in molecular science, it was discovered that cancer cells had experienced a series of driver mutations, or "strikes," which had caused them to proliferate uncontrollably, fail to separate, and successfully invade tissue that is normally healthy[4]**.** Cancer does not have one specific probable cause. According to researchers, cancer is the result of multiple factors interacting with one another. The individual's genetic, environmental, or constitutional traits might be the contributing variables [7] . However, most cancers are caused by alterations, or alterations, to the DNA within your cells. .It is estimated by medical experts that hereditary genetic alterations that are uncontrollable account for 5% to 12% of all cancer cases.Genetic inheritance mutations in genes are common. They may also develop as a result of external factors after birth.These external factors, often known as carcinogens, may consist of: physical carcinogens, such as UV and radiation, light chemical carcinogens, such as alcohol, asbestos, cigarettes, air pollution, tainted food, and water, biological carcinogens, such as bacteria, parasites, and viruses. The WHO Trusted Source estimates that alcohol, tobacco, high body mass index (BMI), inadequate consumption of fruits and vegetables, and insufficient physical exercise may be responsible for around 33% of cancer-related fatalities [12]

1.2 : Types of Cancer

The World Health Organization (WHO) and the Union for International disease Control (UICC) established internationally acknowledged classifications of cancers that take into consideration the histotype, location of origin, morphologic grade, and the extent to which the disease has spread throughout the body.The four standard categorization categories for tumors are as follows: (I) general, based on tissue, organ, and system; (II) particular kind and (III) grade, based on WHO categorization; and (IV) spread, based on the Tumor Node Metastasis (TNM) system. The fields of clinical oncology, cancer research, and oncologist and pathologist education have all been significantly impacted by these categories. Hematological cancers are categorized distinctively from solid neoplasms in the broad tumor classifications based on the tissue or organ of origin. Solid neoplasms are further defined as carcinomas. Which is frequently diagnosed and they can develop in the skin, lungs, breasts, pancreas, and other organs or glands.It is called sarcomas if they begin from muscle, adipose, bone, or blood vessels; Cancers of lymphocytes are called lymphomas.Lymphomas arise in the

lymphoid tissue. Any blood-related cancer is leukemia. Usually, it doesn't develop into solid tumors. Cancers called myeloma develop in the cells that produce the skin's pigment [6]



FIG 01 : Types of Cancer based on Occurrence

The list of frequent cancer types includes the cancers that are diagnosed with the highest prevalence worldwide, according to cancer occurrence and death statistics from the National Cancer Institute and other sources includes : breast cancer , lung cancer , colorectal cancer , cervical cancer , prostate cancer , bladder cancer , pancreatic cancer , etc.

According to the American Cancer Society's most recent forecasts, the prostate in men and the breast in women are the primary points of new cancer cases. , with an estimated 300,590 new cases in the US in 2023. The prevalence of colorectal and lung cancer is comparable in both sexes. The fourth most frequent cancer in males is bladder cancer.There will be a total of 153,020 new instances of colorectal cancer in 2023, with an estimated 106,970 new cases of colon cancer and 46,050 new cases of rectal cancer.



FIG 2 : statistical percentage of occurrence of different types of cancer individually in men and women (Nasir et al ., 2020)

1.3 : Cell Penetrating Peptides for Cancer

Cell Penetrating Peptides are frequently employed in numerous anti-cancer therapeutic regimens as CPPs are an appealing prospective option for treatment for cancer. Cancer is one of the greatest causes of fatalities worldwide, and because of the complexity of it, it is very complicated to cure. Cell-Penetrating Peptides (CPPs) are peptides that have the ability to bring a wide range of physiologically relevant conjugates (or cargoes) into cells.As a result, they show enormous potential for the identification and treatment of many cancer types[39]. The potential of CPPs to move molecules that are biologically relevant across cell membranes renders them attractive options for a variety of drug transport purposes.

Significant preclinical and clinical proof has been revealed by cell-penetrating peptides to overcome the drawbacks of traditional chemotherapeutics. In preclinical research, some medications have been linked to cell-penetrating peptides in an effort to target malignant tumors. Peptides have considerably more possibilities for cancer diagnosis and treatment. The most adaptable objects, peptides hold tremendous potential for the advancement of cancer treatments and diagnostics. They may be used in a wide range of methods to target cancer cells with treatments, including by impersonating natural proteins to either increase or limit signaling or by acting as a transbarrier delivery mechanism [22] . By specifically delivering drugs to tumors, CPPs can reduce not on target adverse effects and avoid many of the problems associated with treating cancer with

traditional treatments. Such is not possible with the conventional chemotherapeutics that are currently in use. These peptides may be functionally correlated with a wide range of chemotherapeutics, including tyrosine kinase inhibitors, antitumor antibodies, and nanoparticles. This opens the prospect of delivering both known and new cancer treatments directly to tumor tissue [36]. While conjugated products, including anti-cancer medications, can translocate to pass the cell membrane, most chemotherapeutic treatments lack tumor cell selectivity. Furthermore, the co-administration of CPPs with anti-cancer medications can enhance drug transport, accumulation, and half-life in tumor cells as well as cell membrane permeability[47]

Recently conducted research has demonstrated encouraging outcomes for CPP drug conjugation compositions to penetrate the blood-brain barrier and target brain tumor cells[38]. Particular examples include penetratin and TAT, which can penetrate the central nervous system and hence act on malignancies like glioblastoma multiforme (GBM). It has also been demonstrated that these aforementioned peptides when combined with conventional chemotherapy drugs like doxorubicin and paclitaxel cause the death of cancer cells of the lung, breast, and liver,, according to order. The binding of another CPP, bombesin (MG2B), to magainin 2 (MG2) had remarkable anticancer effects in several malignancies, including esophageal cancer. Additional examples are the CPP p28 and CopA3, which selectively reduced the viability of gastric cancer cells.Furthermore, in initial experiments, this peptide's anticancer tumor activity was assessed on cancers of human breast , prostate , ovarian , and melanoma cells in vitro, which promoted cell cycle arrest and high expression of p53[38]

1.4 : Aim of the project

Cancer constitutes one of the world's foremost causes of death. Globally, there were 9.5 million cancer-related fatalities and 18.1 million instances of new cancer in 2018 . According to projections, 6% of people worldwide will suffer from cancer in 2019.The overall death toll is rising in tandem with the world's population growth. From about 46 million in 1990 to 56 million in 2019, there have been more fatalities. Between 1990 and 2019, there was a 21% increase in the world's overall cancer-related death rate . It has been anticipated that by 2040, there might be 29.5 million instances of cancer per year and 16.4 million deaths from cancer [35]

The intracellular drug administration has tremendous potential with the implementation of cell-penetrating peptides. Cancer treatments are an essential clinical use for cell-penetrating peptides. Drug delivery based on cell penetrating peptides has the potential to improve the effectiveness of oligonucleotide- or traditional small-molecule-based therapies by increasing drug absorption in tumor cells.

This review emphasizes the employment of cell penetrating peptides as drug delivery systems in cancer treatment; cargoes and delivery, as well as recent researches are covered, along with potential future applications, transducible agents and activatable cell-penetrating peptides combined with cell-penetrating peptides

1.5: Objectives

-To give an idea about Drug delivery using Cell Penetrating Peptides for the treatment of cancer

- To know more about the comparision between conventional treatment and advanced treatment using cell penetrating peptides for Cancer

- In order to know more about the future prospects and scopes of cell penetrating peptides for the research , diagnosis and treatment of cancer

- Also disscused the optimisation strategies to overcome the clinical limitations of CPPs.

Chapter 02 : Methodology

The following research article discusses the importance and scope of using cell penetrating peptides as an advanced drug delivery system and therapeutic aproach for the treatment of cancer. The advantages and limitations as well as their comparison with the currently available conventional cancer treatments . Moreover clinical limitations of cell penetrating peptides with recently developed strategies to overcome those limitations together with the current status and future prospects also have been discussed. The main focus or goal of this review was to highlight the importance and requirement of Cell penetrating peptides over the conventional treatment of cancer . In order to justify these research goals many already published articles , papers and websites such as Pubmed , Springer, Science Direct , Frontiers, Research Gate , Spandidos publication etc. were reviewed .

Chapter 03: Cell Penetrating peptide as a modern intracellular drug delivery system

A diversified family of peptides with unique characteristics, cell penetrating peptides are especially advantageous for the delivery of practically any kind of substance. having the property of being able to pass through cell membranes without compromising their structural or functional stability; these substances have been extensively studied for their potential to transport medicines, bioactive compounds, and theragnostic components inside of cells. Because of this, CPPs are extensively studied in the context of several conditions, including cancer, diabetes, and genetic abnormalities, in drug delivery applications.Numerous research and publications have demonstrated the effectiveness of CPPs in facilitating the intracellular transport of various bioactive compounds, including as proteins, siRNA, anticancer medicines, DNA, nanoparticles, oligonucleotides, and other peptides.

The capability of Cell Penetrating Peptides (CPPs) to permeate cellular membranes and carry different kinds of cargo, such as drugs, nucleic acids, and detecting agents, to the target cells and tissues makes them highly promising as a therapeutic and diagnostic tool. Preclinical research on CPP-based therapies has shown encouraging findings for the treatment of a number of conditions, including cancer, genetic abnormalities, and neurodegenerative diseases.The amino acid composition of CPPs ranges from 5 to 30 and they have been obtained from a variety of sources, including signal peptides, endogenous viral proteins, antimicrobial peptides, and artificial peptides produced from designed libraries.Several CPPs have a certain conformation, such as a β-helix or β-sheet structure, however many do not. The general heterogeneity of these peptides makes it difficult to define CPPs strictly within a structural and physio-chemical framework. This difficulty is further compounded by the wide range of potential internalization mechanisms, which can be broadly classified as either energy-independent (direct translocation) or energy-dependent (endocytosis). In turn, a number of variables, such as inherent physiochemical features, cell type, membrane characteristics, CPP concentration, ambient temperature, incubation period, and cargo type, may affect the internalization process for a particular CPP[10]

CPPs are classified as cationic, amphipathic, and hydrophobic based on a variety of chemical and structural characteristics. These have several names, including membrane transduction peptides (MTPs), CPPs, Trojan peptides, and protein transduction domains (PTDs). They have minimal cytotoxicity, high internalization, simplicity of manufacturing, and the ability to modify sequences(Javadzadeh & Bahari, 2017)Bacterial membrane proteins, homeoproteins, heparin-binding proteins, DNA-and/or RNA-binding proteins, and signal peptides are all capable of producing CPPs.Pep's-1 (from HIV-1 the reverse transcriptase conjugated towards SV40 NLS), Tat (that is, from HIV-1 transcriptional activator protein), C105Y (that is, from HIV-1 glycoprotein 41), the MPG (from HIV-1 glycoprotein 41 conjugated by its nuclear localization sequence (NLS) coming from simian virus 40 (SV40), pepR as well as pepM (from Dengue virus), and VP22 (from Herpes simplex virus-1) are just a few of the viruses from which several CPPs originated.Another common source of CPPs is human proteins, which has the benefit of reducing potential toxicity and immunogenicity in vivo. Numerous CPPs generated from proteins, including VectoCell, Lactoferrin, Sim-2, and 2IL-1a, have been found. Additionally, a lot of CPPs come from naturally occurring sequences that have been strategically altered to improve penetration and stability properties or avoid certain undesirable side effects including cytotoxicity[10]

3.1: Classification

It is challenging to determine the appropriate classification criteria for CPPs due to their extreme diversity as a category of compounds.The subfamily of CPPs has grown significantly during the past three decades of the cell-penetrating peptides period, and the search for novel sequences is still ongoing.CPPs have been recognized by researchers for their utility in the transduction of a wide range of chemicals and particulates into cultivated cells in addition to in vivo..In recent years, different systems of classification have been proposed based on various factors such as physicochemical properties (such as charge, amphipathicity, hydrophobicity, etc.); their structural characteristics (such as β-sheet, α-helical, PP-II helix, random coil, or a combination of them); origin (from natural proteins, semi- or fully synthetic); applications (cargo delivery, bioimaging, modulators of biochemical events, e.g., bioportides) and acceptance methods.

3.1.1: Classification Based on Origin

CPPs can be classified as synthetic, chimeric, or protein-derived CPPs depending on where they originated from.CPPs formed from proteins are a component of the native protein structure that can pass across membranes. Protein-derived CPPs, often referred to as membrane translocation sequences or protein transduction domains, typically comprise the least effective partial sequence of the parent translocation protein. Two separate peptides are combined to form chimeric CPPs.Since this set of CPPs includes sequences comprising more than two different naturally occurring proteins, it is widely acknowledged as a transition from natural to synthetic CPPs. Examples include the twenty amino acids amphipathic peptide (CADY), which contains cationic such as- (arginine, R) and aromatic such as- (tryptophan, W) residues.Artificial design goes into creating synthetic CPPs. Because of their excellent cellular absorption efficiency, polyarginine 8–10-mers are the most researched belonging to this class.

3.1.2: Classification Based on Physiochemical properties

CPPs may be divided into three main classifications based on variations in their physicochemical characteristics: hydrophobic, amphipathic, and cationic CPPs. The positive charge of cationic CPPs exhibits exceptional affinity for the cytoplasmic membrane at pH values relevant to physiological circumstances. Through an electrostatic collision, the cationic CPPs join with the negatively charged glycoprotein in the cell membrane, which is then internalized into the cell by a method that does not rely on the receptor. Over five positively charged amino acids are typically present in the majority of cationic CPPs. The example of cationic cell penetrating peptide including arginine and lysine residues is the HIV-1 transcriptional activator protein (TAT)Because of the lysine residues in their structures, amphipathic CPPs are sequences that exhibit a high degree of amphipathicity. With over 40% of cases, amphipathic CPPs are the most prevalent. There are both non -polar and polar amino acid areas in amphiphilic CPPs, and the non-polar in nature parts are rich in hydrophobic amino acids, such as alanine, valine, leucine, and isoleucine.. Certain amphiphilic cell penetrating peptides , such pVEC and ARF (19–31), are purely generated from natural proteins.Just non-polar

and hydrophobic pattern sequences are present in hydrophobic CPPs. Hydrophobic CPPs are relatively rare, and their structures contain several residues that are not polar or very few asserted amino acids (in excess of 20% of the sequencing).Thus far, natural hydrophobic CPPs have been identified as K-FGF Bip4, and C105Y[45]

Table 01 :

Classification Based on Physiochemical properties			
Class	**Peptide**	**Sequence**	**Reference**
Cataonic	TAT	GRKKRRQRRRPPQ	[45]
	Antp	RQJKIWFQNRRMKWKK	
	8L-Lysine	KKKKKKKK	
Amphilic	MPG	GLAFLGFLGAAGGAWSQPKKKRKVSTM	[45]
	VP22	NAATATRGRSAASRPTQRPRAPARSASRPRRPVQ	
	PePI	KETWWETWWTEWSQPKKKRKV	
Hydrophobic	Azurin p18	LSTAADMQGVVTDGMASG	[45]
	Transportan	GWTLNSAGYLLGKINLKALAALAKKI	
	FGF	PIEVCMYREP	
Classification Based on Origin			
Class	**Peptide**	**Sequence**	**Reference**
Chemeric	Transportan	GWTLNSAGYLLGKINLKALAALAKKIL	[45]
	Ig(V)	MGLGLHLLVLAAALQGAKKKRKV	
Synthetic	Amphiphilic model peptide	KLAKLALKLALKALKAALKLAKLA	[45]

Protein - drived	pVEC	LLIILRRRRIRKQAHA HSK	[45]
	HRSV	RRIPNRRPRR	

3.2 : Application

With the exception of proteins and nanoparticles, CPPs were also utilized to facilitate the cellular absorption of extracellular vesicles. Poly-arginine was added to extracellular vesicles to enhance internalization through the induction of active micropinocytosis; the quantity of arginine residues affected the efficiency of cellular internalization. Extracellular vesicles modified with the hexadeca-arginine (R16) peptide demonstrated a rather efficient anti-cancer effect.

CPPs coated nanoparticles with polyanionic compounds, such as Hyaluronic acid, a high-affinity ligand for the overstated CD44 marker seen on tumor surfaces. The utilization of liposomes coupled with HA and CPPs via ultrasound was a favorable and promising technique for CPPs delivery in vivo; this group displayed much higher tumor suppression towards hepatic carcinoma compared the rest of the groups. The unfavorable prognosis of oncotherapy, particularly for pancreatic cancer, gliomas, and lymph metastases, constituted a significant obstacle. Because delivery devices could not get beyond the complicated tumor microenvironment to get medications to the treatment site, there was little progress made in curing resistant cancers. CPPs may be utilized as a molecular propellant to enable cargos to deeply penetrate malignancies. Collagenic fibers were widely distributed in the tumor stroma of pancreatic ductal adenocarcinoma (PDAC) in order to prevent drug penetration[20]

Delivery of Nucleic Acids and Oligonucleotides in Gene Therapy:

Effectively transferring genetic information into a living cell or tissues or entire organ without creating harmful consequences is known as gene therapy. However, low concentrations of DNA and other Oligonucleotides reaching their targets were caused by eukaryotic cells' limited permeability of their plasma membrane to DNA. In order to get around this problem, peptide carriers of the polylysine and polyarginine combined membrane-destabilizing features can bond to DNA via electrostatic contact (i.e., non-covalently bound form) and promote Translation of genes towards cells. By connecting PEI to TAT a CPP via a hetero-bifunctional polyethylenglycol (PEG) spacer, or TAT-PEG-PEI conjugate, gene transport efficacy in the lung may be greatly improved and in vivo toxicity may be decreased [20]

Delivery of therapeutic Small Molecule as Drugs:

Small-molecule drugs (metabolites) block the function of infectious or cellular proteins that are involved in various phases of the life cycles of pathogens. The majority of small-molecule drugs can penetrate the cell membrane, but occasionally, their high degree of hydrophilicity limits their bioavailability by making it harder for them to do so. As consequently, conjugating CPPs with these small molecule drugs could further enhance their pharmacodynamics and pharmacokinetics profile (e.g., elevated dissolution and bioavailability in small molecular medications throughout body fluids), and additionally enhance their cellular uptake [e.g., the transmission of smaller molecules across the blood-brain barrier].One example of an antiviral medication that can pass the blood-brain barrier and suppress the brain-resident virus linked to HIV that causes HIV-associated cognitive impairment (HAND) in vitro is porphyrin conjugated with CPPs.

Application of CPPs in Central Nervous System Disorders:

By improving BBB penetration, CPPs showed a significant potential for the treatment of illnesses affecting the central nervous system. A crucial technological advancement to go around BBB and improve the therapeutic efficacy was CPPs' changed method. Because the blood-brain barrier (BBB) was made up of closely spaced endothelial cells without fenestrae, it had minimal permeability for the transfer of drugs to the

brain. Due to BBB blockage, the therapeutic impact of incurable illnesses of the central nervous system was not up to par. Therapeutic drugs were delivered to the brain by CPPs through the adsorptive-mediated transcytosis pathway across the blood-brain barrier. At submicromolar concentrations, CPPs demonstrated effective BBB 30 translocation activity without causing cytolytic effects. Furthermore, CPPs may evade P-glycoprotein in order to enhance drug accumulation in the brain and enhance therapeutic outcome. However, the BBB penetration power of various CPP kinds varies[45]

Delivery of imaging agents :

Imaging agents are capable of monitoring or promptly offer information on the therapeutic action of drugs, which is crucial for illness diagnosis. Delivery of imaging agents to diseased tissue is still very difficult, though, because cell membranes block the absorption of many foreign substances. CPPs' exceptional permeability, high affinity, and great stability make them crucial for the delivery of imaging agents. Additionally, a lot of researchers focused on CPPs as imaging agents for diagnosis, leading to some progress in preclinical and clinical studies.

Membrane permeability limits the use of intracellular imaging, which can enhance illness management by identifying disease indicators. CPPs have been thought of in this context as a carrier for delivering imaging substances into cells. When compared to conventional approaches, this technology has the benefit of being able to visualize and analyze biomarkers, detect disease phases, identify the extent of disorders, and assess the impact of treatments[4]

Chapter 4 : Cell Penetrating peptide as a drug delivery approach for the diagnosis and treatment of Cancer

Cancer therapies are an essential clinical use for cell-penetrating peptides. Peptide-based delivery of drugs has the potential to further enhance the effectiveness of oligonucleotide- or traditional small-molecule-based therapies by increasing drug absorption in tumor cells. Cell-penetrating peptides (CPPs) offer a potentially successful treatment for issues often associated with oligonucleotide-based therapies and the drug delivery of traditional cancer chemotherapeutics.

Introducing drugs to cancer patients with CPP-based delivery is an intriguing strategy since it may transport cargo into the cell. It may be possible to deliver both contemporary gene-based medications and traditional chemotherapeutics into tumor cells. One other benefit is that targeting peptides and peptide sequences for cell penetration may be combined to create delivery systems that are specifically targeted.

The number of original research articles and reviews addressing the wide range of uses for cell penetrating peptides (CPPs) has increased dramatically in the past several years. This is not surprising because one of the main issues with medication delivery and targeted therapy is that CPPs may carry a wide variety of cargo across cell membranes

Studies in both Clinical and preclinical research have found that involving cell penetrating peptides as vaccine carriers may produce a strong immune response particular to cancer, especially against less immunogenic "cold tumors." By stimulating the CD8 and the CD4 T cells and triggering versatile immunological retaliation, CPPs enhance therapy. It has been demonstrated that these CPP (Z12) based vaccine peptides produce long-term immune responses for OVA-specific the CD8 T cell immunological reaction and penetratin. Additionally, in tumor re-attack assays, TAT immunity with OVA or HPV-E7 fusion has been demonstrated to be memory-induced[47]

4.1 : Cell-Penetrating Peptides as Tumor Imaging Agents for Cancer therapy

CPPs are an intriguing tumor detection approach because to their substantial binding affinities small size, selective uptake, high stability, rapid removal from unspecific targets, and retention in specific targets.These imaging agents can be carried, transported, and delivered by CPPs, giving the imaging cargo intracellular functioning and access.Using dual targeting using cell penetrating peptides is a further approach to improve tumor targeting. To improve its targeting capability, the cell penetrating peptide is conjugated with another agent in this technique. It reveals a promising combination of CPP- (F3) and CPP-NP for tumor imaging, indicating that several CPP variants and combinations are available to enhance tumor imaging [24] **.** Activatable CPPs are a second approach to improve tumor imaging (ACPPs). The CPP in this technique consists of three regions: a region that targets metalloproteinase -2 (MMP-2) and MMP-9 (protease-cleavable intermediate), a section that may circulate cargo into cells (polycation), and a continent that suppresses the activity of the cell-penetrating region.

4.2 : Cell-Penetrating Peptides as a vector for targeted delivery of drugs to tumors in cancer treatment

When a tumor-targeting drug was administered along with a cell-penetrating peptide, the drug's penetration into the extravascular space of the tumor was tumor-specific. It's interesting to note that peptide co administration has raised the therapeutic indices of a wide range of tumor-targeting medications, including monoclonal antibodies, NPs, and small molecule chemotherapeutics. So, one potential way to get around the present chemotherapeutics' limited penetration is to combine these tumor-targeting medications with cell-penetrating peptides, which improve tissue permeability. The potentiality of cell-penetrating peptides to circumvent problems with drug restistance previously observed with contemporary anticancer drugs is another potential area of advancement in this field. Further, a lower general dose of drugs can be employed so that the body's inherent processes that generate resistance are less of a problem because of the efficient targeting and transduction of pharmaceuticals connected to CPPs Anticancer therapy can efficiently accumulate in the tumor by being coupled to a targeted ligand for these receptors, which increases the therapeutic impact and reduces adverse effects[36]. Surprisingly, recent studies claim that a second general

mechanism called the bystander effect may also be involved in drug delivery using cell-penetrating peptides . The method described above allows for the concurrent administration of a drug cargo without requiring the drug be attached covalently to the cell-penetrating peptide. The C-end Rule (CendR) method of administration, an endocytic transport process comparable to but distinct from micropinocytosis, is responsible for this bystander effect. It has been demonstrated that the peptide that triggers this pathway is iRGD. The CendR pathway is activated when this peptide attaches to a tumor-specific receptor, cleaves proteolytically, and then attaches to neuropilin-1, another receptor[36]

To deliver anticancer medications, iRGD and the CendR pathways have been used in several preclinical experiments. When iRGD was co-administered with a wide range of drugs for cancer, all of them experienced a rise in their therapeutic indices . In a different research, gemcitabine's anticancer effects were amplified when combined with Irgd in a model of mouse with pancreatic cancer that overexpressed neuropilin-1 . Studies focusing on hepatocellular carcinoma and gastric malignancies have shown similar findings These fruitful preclinical studies, which combined the administration of chemotherapy iRGD containing drugs , verify the CendR pathway and provide the groundwork for upcoming research.

Conjugating siRNAs with CPPs is a potential new direction in clinical research for cancer therapy in general.. SiRNAs have demonstrated significant promise in the treatment of cancer; nevertheless, the lack of a reliable and efficient delivery system has hindered their use in clinical applications .Preclinical studies have give a demonstration of the potentiality of CPPs as secure and efficient delivery systems for siRNA that target tumors. In animal models, a variety of peptides, including CPP33, gh625, PD-L1, and PEG-SS-PEI, have been successfully combined with siRNA to target different types of cancer.These CPPs have demonstrated improved antitumor effects in mice model with lung, breast, and liver malignancies, among other cancer types, due to their siRNA loads[36]

4.3 : Delivery of chemotherapeutic compounds using Cell penetrating peptides

Drugs associated with chemotherapy have long been made use of to treat cancer because of their ability to stop cancer cells from spreading, multiplying, and attacking other cancer cells. In general, the majority of chemotherapeutic medications lack selectivity towards tumour cells, but CPPs may accelerate the translocation of linked products, such anti-cancer drugs, across the cell membrane. Furthermore, the incorporation of CPPs in combination with anti-cancer drugs can enhance drug transport, accumulation, and half-life in tumor cells by increasing cell membrane penetration

Although the anticancer medication camptothecin has a strong capacity to suppress tumor growth, it is too hydrophobic to dissolve in water, which restricts its potential for more distant clinical usage and also damages DNA. By developing an innovative pH-activatable CPP, LHHLLHHLHHLLHH-NH 2(LH), the conjugate exhibited increased anti-cancer efficacy that is pH dependent

Curcumin exhibits antioxidant and anti-inflammatory properties, however its toxicity in high doses is negligible. A CPP-mediated CUR nano-micelle has been proposed to effectively accumulate chemotherapeutic drugs in glioblastoma multiforme (GBM) tumor cells.

Paclitaxel(PTX) is another anticancer drug . The water solubility of PTX-CPP is designed based upon the benefit that most of the cell penetrating peptides are hydrophilic, so avoiding the repercussions of employing inorganic solvents to diminish the efficacy of the medicine. The conjugates PTX-LMWP and PTX-TAT were created to overcome PTX's low solubility and resistance. It has been demonstrated that PTX-CPPs increase cellular absorption and cause apoptosis in A549 and A549T cells to stop tumor development. Small molecule doxorubicin is a chemotherapy drug used to treat solid tumors, however its cardiotoxicity and the possibility of DOX-resistant tumors restrict its potential therapeutic uses. It has been demonstrated that the amalgamation of CPPs and DOX (CPP-DOX) has greater therapeutic efficacy and less cytotoxicity when compared to the single medication DOX. clinical trials utilizing some of the CPPs in anticancer therapies . A

high-dose chemotherapy medication called methotrexate (MTX) is used to treat cancerous tumors in both adults and children. These tumors include breast cancer, lung cancer, osteosarcoma, lymphoma, and acute lymphoblastic leukemia. MTX, however, may be harmful to the body's natural organs and tissues and has inadequate tumor targeting and stability. YTA2 and YTA4, two distinct CPPs, were coupled to MTX. It has been demonstrated that peptide-MTX conjugates can destroy cells much more effectively than MTX alone and can overcome MTX resistance. It was discovered that the DDS improved the capacity to target breast cancer and partially resolved the issue of medication resistance.

Tamoxifen (TAM) is a popular oral hormone anti-tumor medication that has a number of adverse effects but can be utilized for the treatment of ER-positive cancers of the breast and ovaries, and other malignancies. To overcome these limitations, a number of RID-F peptide conjugates have been developed extensively[47].

4.4: Delivery of biological molecules for therapeutic purposes of Cancer Treatment

Cancer is usually brought on by mutations in imperative genes, and studies have shown that the NA gene therapy can have a satisfactory anti-tumor impact. Conventional NA medications include plasmid DNA (pDNA), messenger RNA (mRNA), small interfering RNA (siRNA), and antisense oligonucleotide (AON).NAs are strongly charged anionic molecules which can be swiftly evacuated from systemic circulation. Thus, perhaps the most complicated challenge associated with gene therapy is to solve the concern of targeted delivery. In most situations, the anionic charge and spontaneity binding to cation CPPs via electrostatic interaction are considered CPPs for NA administration.CPPs provide a number of activities in CPP/NA 36 combinations, which includes are shielding NAs from nucleases, increasing cell intake and targeting particular cells.CPPs can introduce membrane-impermeable chemicals into living cells with a minimal immunogenic reaction making them safer and capable of loading more genes than viral methods.Combining CPPs with NAs addresses the low permeability and stability of NAs while enabling efficient intracellular delivery

CPPs are currently a widely employed delivery method for the effective introduction of siRNA into cells.The use of CPPs to introduce siRNA into cells and enhance the restrictions on the administration of siRNA drugs has gained widespread acceptance.Preclinical research indicates that CPPs have a promising future as a secure and reliable carrier for siRNA targeting to tumors. Combining siRNA with a variety of peptides has been very effective in targeting cancer in animal models. In vivo studies in mice utilizing the MCF-7 xenograft model revealed that siRNA-CPPs/TML had improved targeted delivery, anti-cancer efficacy, and gene-silencing efficiency. CPPs can also assist carry DNA into cells and, in some situations, to the nucleus.When the peptide was coupled with pDNA, the cationic DNA-loaded NPs assembled itself to create a stable NP. The RALA/pDNA NPs combination might preserve NA medicines from decomposition by enzymes while also delivering them to the intended locations, allowing for gene delivery along with individualized therapy of human breast cancer[47] .

4.5 : Delivery of proteins for anticancer therapy

Anti-tumour antibodies that attach to CPPs may pass through barriers in the membrane caused by the antibody sizes. Several techniques have been devised for effectively introducing antibodies to cancer cells via CPPs. mAb (CEA mAb)-TAT-gelonin is a treatment approach to colon cancer that uses an anti-cancer embryonic antigen. The compound CEA mAb-TAT-gelonin revealed greater penetration in vivo and in vitro, indicating that it can carry greater amounts of antibodies into cancer cells. Along with that, CPP-3E10 is an antibody that can recognize and additionally attach to the N-terminal of RAD51, preventing it from pairing to DNA and causing damage and cancer.This intracellular protein delivery technique for nano-molar level antibodies is simple yet extremely effective, and it signifies as one of the most recent advances in protein transfer. It is predicted to accelerate the development of anti-cancer medicines that involve intracellular antibody delivery.

Fusion protein is a novel type of reconstituted protein formed by combining components of immunoglobulin with targeting proteins such as cytokines, receptors, antigenic peptides, and other proteins that are biochemically functional. In addition, a subset of CPP fusion proteins is designed to deliver tumor-associated antigens to APCs, inducing tumour-specific immune responses and improving CTL conclusions.In this instance, the determination or purification of tumor antigens is not required for the use of CPP fusion proteins in different tumor immunotherapies. As a result, an anti-cancer medication including FOXM1 protein peptides and CPP can be created to allow therapeutic proteins to penetrate cancer cells and perform anti-cancer functions.

ACPs, or anti-cancer peptides, are short proteins that may be derived from both naturally occurring and synthetic peptides. Several studies have combined ACPs and CPPs to enhance their anti-tumor effects by specifically targeting the medicine to destroy tumor cells. They were just recognized as cationic polypeptides obtained from diverse species prior to its use as a potent anti-cancer medication.ACPs perform better in preventing the growth and migration of tumor cells as well as the migration of blood vessels found in tumors than traditional chemotherapy medications.

Pre-clinical and clinical research have indicated that employing CPPs as a vaccine vehicle can elicit a strong cancer-specific immune system response, especially against 'cold tumours' that have characteristics that are less immunogenic.GV1001, an anti-cancer vaccine peptide, has been found to treat advanced pancreatic cancer, non-small cell lung cancer, melanoma, and prostate cancer[47]

4.6 : Preclinical -Clinical studies already has been done to diagnos and treat different types of cancer

Breast cancer : Globally, breast cancer is the primary cause of cancer-related deaths among women. Therefore, there is an urgent need for effective medication with minimal side effects for the treatment and prevention of breast cancer. A wealth of data indicates that cell penetrating peptide-based therapeutic approaches, when combined with high levels of safety and adaptable features, have great promise for the

treatment of breast cancer. Cell penetrating Peptide-based vectors have garnered interest in the fight against breast cancer lately because of their ability to specifically attach to overexpressed receptors in cells.

Hydrophobic and electrostatic attraction allowed CPPs to cross cytomembranes, which allowed the delivery of anticancer drugs into breast cancer cells.For the purpose of treating breast cancer, CPPs and numerous drugs that enter cytomembranes by endocytosis or direct penetration increase the anticancer efficacy of compounds that are difficult to penetrate.

Precisely to the mildly acidic conditions around the tumor, which was generally pH 6.0, the researcher constructed a pH-activatable CPP dimer LH2 to deliver paclitaxel to triple negative MDA-MB-231 cells. The study nonetheless went on to evaluate the capacity of CPP C coupled with peptide SP90 to target breast tumors, particularly triple negative MDA-MB-231 cells. SP90-C revealed a well-targeted delivery function for anticancer medicines[23].

Treatment with chemotherapy medicines frequently have insufficient internalization by TNBC cells, thereby rendering it difficult to treat triple negative breast cancer (TNBC).Based on the preceding studies, it was discovered that CPPs have been studied more in order to improve the way chemical drugs or siRNA penetrated cells in order to cure TNBCs. Numerous CPPs, including peptide dimer LH2, peptide C, cCPP, peptide gH625, peptide GALA, and peptide tLyP-1, were chosen to enhance internalization in order to transfer chemical medicines or siRNA to treat TNBCs

A new TAT-based peptide delivery system was effectively created in another study that subsequently can deliver a therapeutic peptide called STAT3BP, which inhibits STAT3 activation and specifically stops the growth of ErbB2-overexpressing breast cancer cells both in vitro and in vivo, in a target-specific manner. This technology may also be utilized to administer other medicines that are chemically amendable, and it may be very useful in the development of next-generation targeted cancer therapies[23]

A separate study found that administering the cell penetrating peptide iRGD in conjunction with nab-paclitaxel, an albumin-bound version of paclitaxel, effectively treated a previously resistant xenograft of breast cancer [36]. In research a CPP-GNP framework comprising TAT peptide-modified AuNPs containing doxorubicin was created to improve drug administrtion to retrict breast cancer cells. A discernible decrease in IC50 indicated that the cytotoxicity in the cell line with breast cancer was substantially enhanced as compared with unbound drugs.When CPP is combined with chemotherapy therapies like SynB1, paclitaxel is delivered to breast cancer cells, causing tumor cell cycle arrest and tumor cell death[47]

Prostate cancer :

The most prevalent cancer in males is prostate cancer. In 2020, about 1,414,259 individuals were given aprostate cancer diagnosis worldwide. Only one in 39 men will pass away from it, while around one in nine men will receive a diagnosis of it throughout their lives. Approximately 80% of males who become 80 years old have prostate cancer. For males aged 15 to 49, the survival rate from prostate cancer is 91%. In those aged 60 to 69, it reaches its maximum rate of 94%. After that, the 80–99-year-old group's survival percentage falls to 66%

In order to reduce drug systemic toxicity and increase bioavailability, tumor-homing peptides have drawn a lot of interest as techniques for the development of non-invasive and targeted drug delivery systems (DDS). This work attempts to enhance antitumor targeting in prostate cancer by uploading a medication to a drug delivery system (DDS) that is made up of a cell penetrating peptide adorned with PL3, a peptide that locates tumor in prostate

It has been shown that the severity and propensity for metastasis of prostate tumors are correlated with the overexpression of integrin α(2)β(1). According to a recent publication, the DGEA peptide shows promise as a targeted ligand for integrin α(2)β(1) expression in prostate tumors using microPET imaging and near-infrared fluorescence. By adding a number of cell-penetrating peptides (CPPs) to the DGEA sequence, researchers hope to increase the targeting efficacy of these peptides[16].

Lung cancer :

In 2020, there is likely to be 2,206,771 new cases of lung cancer diagnosed worldwide.These statistics consist of both NSCLC and small cell lung cancer. In average, a man's lifespan chance of acquiring lung cancer is roughly 1 in 16, while a woman's risk will be around 1 in 17[28]

In a research study, a cell-penetrating peptide called CPP33 that had been loaded with siPLK1, a siRNA that targets A549 lung cancer cells, showed increased endosomal escape as well as increased blood circulation, improved tumor accumulation, and efficient tumor growth inhibition[36]According to a recent study, paclitaxel can be administered to drug-resistant lung cancer using TAT and LMW in order to influence tumor cell mitosis and prevent tumor development.The selective CPP (RLWMRWYSPRTRAYGC)-functionalized polymer (SCPP-PS) is responsible for the efficient and targeted delivery of MTX to human lung cancer cells in vivo. When comparing MTX-SCPP-PS to the free groups, MTX and MTX-PS showed much lower IC values and the highest tumor growth rate[47]

Progesterone receptor polyproline domain-containing cell-penetrating peptides may prevent EGF-induced cell growth in NSCLC cells. To aid in the delivery of PR-PPD into NSCLC cells, it was coupled to Buforin2 (BR2), a CPP that is specific to tumors. It's significant to note that BR2-2xPPD peptides, which include two PR-PPD repetitions were more successful in suppressing the growth of NSCLC and greatly lessened the phosphorylation of Erk1/2 that is caused by EGF. In EGFR-wild type A549 cells, BR2-2xPPD therapy caused cell cycle arrest by preventing the expression of the CDK2 and cyclin D1 genes.The results of this study highlight the possible function of BR2, a tiny peptide that enters cells and selectively targets cancer cells while sparing healthy ones. Together, the research findings reveal proof of concept for the potential use of a cancer cell-specific CPP in conjunction with PR-PPD as a new therapeutic agent.

Cervical Cancer:

In the world, cervical cancer ranks fourth in terms of frequency among women; in 2022, there were around 660 000 new cases and 350 000 fatal cases. The following are the 5-year relative survival rates for cervical cancer: 91% of women with cervical cancer survive five years when the disease is detected early. The 5-year relative survival percentage for cervical cancer patients who receive a diagnosis after the disease has progressed to adjacent tissues, organs, or regional lymph nodes is 60%[44] . In preclinical models of HPV16-induced cervical cancer, inoculating unadjuvanted LALF(32-51) (an antigen-associated Limulus polyphemus protein) -E7 (an HPV antigen) fusion protein substantially enhanced the ability to present of E7-derived cell penetrating peptides to T cells in vitro and inhibited tumor growth[47]

Bladder cancer :

Cell Penetrating R11 Peptide was implemented by a researcher to diagnose bladder cancer. Based on the findings, FITC-R11 has been proven to be a more specific molecular probe for BCa than normal bladder tissue, and it may find use in therapeutic settings. Furthermore, compared to normal bladder tissues, the BCa tissues of the patients had a substantially increased FITC-R11 uptake efficiency[9].

The most frequent cancer of the urinary system is urothelial carcinoma of the bladder (UCB), of which around half have a TP53 gene mutation. Therefore, a treatment strategy that involves giving cancer cells their functioning p53 protein will be advantageous. Recent research has shown that p53 reactivation using a peptide generated from the p53 C-terminus (p53C) inhibits the development of cancer cells. Preclinical orthotopic and metastatic bladder cancer animals treated with the R11-p53C peptide showed a substantial reduction in tumor burden and an extension in survival time without a discernible cytotoxic effect. Based on these findings, the R11-p53C peptide was thought to have therapeutic promise for bladder cancer,both primary as well as metastatic, and R11-mediated transduction may be an acceptable method for clinically introducing large tumor suppressor molecules to tumor cells[46]

Colorectal cancer :

Colorectal cancer is also known as cancer of the bowel, cancer of the colon, or cancer of the rectal.Approximately 10% of all cancer cases globally are colorectal cancer instances, making it the second most frequent disease worldwide and the second biggest cause of fatalities due to cancer. In general, 1 in 25 women and 1 in 23 men will acquire colorectal cancer throughout their lifetimes. Globally, it was estimated that there will be over 1.9 million new cases of colorectal cancer and more than 930,000 deaths from the illness in 2020 [44]. One of the primary active ingredients in the treatment of colorectal cancer is oxaliplatin, a platinum-based drug. Oxaliplatin may be delivered to colon cancer cells efficiently and quickly with the use of a CPP-R8-oxaliplatin combination. Additionally, the combination demonstrated a reasonably high capacity to target tumors in vivo and may effectively limit tumor development [47]**.** An CPP identified with Cy5 was utilized in a recent study to scan and target colorectal cancer. Utilising HCT-116 xenograft nude mice, in vivo and ex vivo fluorescence imaging was carried out utilizing an IVIS imaging system.The study findings showed that ACPP-Cy5 persisted in liver metastases and malignancies, indicating its potential as an imaging agent for the detection of both tumors and metastases in colon[36]

Others :

The application of CPP-conjugated polymer micelles is a rapidly developing area of study in the area of tumor-targeted treatment. For instance, TAT peptide-containing micelle systems have been effectively used by researchers to target solid tumors with anti-cancer medications, yielding encouraging experimental outcomes .Numerous instances of CPP and liposome medication delivery have been seen to assist in bridging the blood-brain barrier for improved treatment outcomes with neurologic tumors.According to the already experimental findings, CPPs have a promising future as a secure and reliable carrier for siRNA targeting to tumors in preclinical investigations. Combining siRNA with a variety of peptides has been very effective in targeting cancer in animal models.According to the already experimental findings, CPPs have a promising future as a secure and reliable carrier for siRNA targeting tumors in preclinical investigations. Combining siRNA with a

variety of peptides has been very effective in targeting cancer in animal models[47] . Research has shown that when paclitaxel and Cpp were combined, the treatment response for ovarian cancer was 4.8 times greater than when paclitaxel was used alone. Additionally, it has been demonstrated that 11 poly-arginine peptides (11R) inhibit the growth of oral cancer[36] Multiple strategies have been established to effectively deliver antibodies to cancer cells that possess CPPs. A researcher developed a colon cancer treatment plan based on anti-cancer embryonic antigen mAb (CEA mAb) TAT gelonin. By showing increased penetration both in vivo and in vitro, the combination CEA mAb -TAT-gelonin can carry more antibodies into cancer cells.Peptide LY6K-177 (RYCNLEGPPI), which is overexpressed in a number of cancerous tumors, including gastric cancer, is derived from LY6K and is intended for this target; in immunotherapy, this peptide shows promise.Prostate cancer, non-small cell lung cancer, melanoma, and advanced pancreatic cancer all responded to being treated with GV1001, an anti-cancer vaccine peptide

Chapter 5: Clinical trials , drawbacks and modification strategies for Cell Penetrating peptides

5.1: Certain CPP-based anti-cancer treatments under clinical trials

Promising outcomes for CPP-based diagnostics and therapies have been shown in earlier preclinical research, not only in the field of cancer therapy but also in other therapeutic areas. Positive results from trials using CPPs to examine the effectiveness of CPP-based therapies for cancer medications and diagnostics further highlight the diverse spectrum of potential therapeutic options.

A first-in-class, first-in-human phase I study was conducted to assess the assurance, tolerance, pharmacokinetics, and preliminary efficacy of p28 in patients with p53+ metastatic solid tumors and advanced solid tumors. Conclusions show that p28 is well tolerated by the body and does not elicit cytotoxic effects. found to prevent p53 ubiquitination, which prevents the development of cancer cells[3].

Pediatric patients with malignancies of the central nervous system (CNS) were the subjects of a second phase I clinical study with p28 as a single agent . Using a rolling-6 trial design, children with recurring or progressing CNS tumors were given p28 intravenously at 4.16 mg/kg/dose, the adult approved phase II dosage. All age groups may tolerate p28-based therapies, as evidenced by similar outcomes, even if the adult p28 dosage was accepted by the teens. These studies' outcomes have demonstrated that p28 is both safe and well-tolerated when taken at the suggested phase II dosage (RP2D[27].

Generation of a Specific Antibody to Recognize caPCNA. Nonmalignant breast epithelial cells have been shown to carry a single isoform of the PCNA protein with a basic isoelectric point (nmPCNA), according to study utilizing 2D PAGE. On the other hand, it was discovered that the protein was present in both its basic form and its acidic isoform in malignant breast epithelial cell cultures and breast epithelial cells in tissues (caPCNA).

The final outcome demonstrates that caPCNA is an extremely selective antigen that interacts with proteins within cancer cells throughout the DNA repair pathway. The caPCNA-p21 complex, when paired with p21's capacity to trigger apoptosis, is a potentially effective therapy for breast cancer[31].

Presently, ALRN-6924 is being used in two Phase 2 clinical trials that have demonstrated encouraging outcomes in the treatment of cancer, including pediatric instances.BT1718, a different peptide that is presently undergoing clinical trials, is intended to target and decrease the activity of MT1-MMP by identifying and binding to the MT1-MMP protein. Following attachment, it is absorbed by cancer cells [P28 is another CPP that is presently being assessed in two treatment studies related to cancer]. It targets solid tumors that are resistant to conventional treatment procedures and is developed from azurin. After completing their Phase I studies, both of these treatments appear promising for treating solid cancers that are resistant to traditional chemotherapy**.**

Table 2 : Overview of numerous clinical trials with CPPs in anticancer therapy

CPP Employed	**Drug Employed with CPP**	**Targeted Cancer**	**Stage of study**	**ClinicalTrials.gov ID**	**Ref**
ALRN-6924	alone and in combination withpalbocicli b	Solid tumor, lymphoma, and peripheral T-cell lymphoma	Phase1—Completed,Phase2a—Completed	NCT02264613	[36]
ALRN-6924	individually as well as in a combination with cytarabine	myeloid leukemia(acute), and advanced myelodysplastic syndrome	Phase 1—Completed	NCT02909972	[36]
ALRN-6924	In together with paclitaxe	Advanced, and metastatic, or undetected solid tumors	Phase 1	NCT03725436	[36]
ALRN-6924	individually as well as in a combination with cytarabine for patients with leukemia	Pediatric leukemia, pediatric brain tumor, pediatric solid tumor, pediatric lymphoma	Phase 1	NCT03654716	[36]

ALRN-6924	Phase 1b—ALRN-6 924 with topotecan in Phase 2—topotecan individually and in combination	Small cell lung cancer	Phase 1a—Complete d Phase 1b Phase 2	NCT0402286	[36]
BT1718	Alone	Progressive solid tumors, non-small cell cancers of the lungs, non-small cell lung Sarcomas, and cancer of the esophagus.	Phase 1 Phase 2	NCT03486730	[36]
P28	Alone	Refractory solid tumors	Phase 1—Completed	NCT00914914	[36]
P28	Alone	Recurrent or progressive central nervous system tumors	Phase 1—Completed	NCT01975116	[36]
PEP-010	Individually and together with paclitaxel	Metastatic solid tumor cancer	Phase 1	NCT04733027	[36]
ATP128	Individually and together with BI 754091	Stage IV colorectal cancer	Phase 1a—Complete d Phase 1b	NCT04046445	[36]

5.2: Some Cell penetrating peptides-based experiments:

Table 3 :

Cell Penetrating Peptides	Cargoes	Tumor/Cell lines /Model (animal)	In vivo/vitro	Ref.
PEGA-pVEC	EgCG	Breast tumour-bearing mice	In vivo	[47]
KRP	Doxorubicin	Osteosarcoma MG63	In vitro	[47]
R8	Oxaliplatin	Colon cancer	In vitro and In vivo	[47]

R7	DTX	Breast cancer	In vitro	[47]
SCPP-PS	Methotrexate	Mice bearing A549 lung tumor xenografts	In vitro	[47]
LMWP-TAT	Paclitaxel	A549 and A549T cells	In vitro	[47]
R7	Paclitaxel	HeLa cells	In vitro	[47]
LMWP	gelsolin	The 293T, HeLa human cervical carcinoma, CT-26 colon adenocarcinoma cell line, human MCF-7 breast carcinoma cell lines, MG 63 osteoblast cell line and NIH3T3 fibroblast cell lines	In vitro and in Vivo	[47]
Penetratin	KLA peptide, (KLAKLAK)2	The non-small cell lungcancercellline (A549) and theneuroblastoma 153cell line (SK-N-SH)	In vitro	[47]
Transportan 10	LXXLL motif of the human SRC-1 nuclear receptor box 1	Breast cancer	In vitro	[47]
MCaUF1-9(Ala)	GNPs	HeLa, MDA-MB-231 and A431	n vitro	[47]
PEG	GNPs	Breast cancer	In vitro and In vivo	[47]
TATp	pH-sensitive PEG polylactic acid micelles	MCF-7	n vitro	[47]
TAT	MWCNTs	Human breast cancer cell line MD-MBA-231 cells	In vitro and In vivo	[47]
TAT, Penetratin	liposomes	SK-BR-3, MCF-7, HTB 9, ADR, A431,C26	In vitro and In vivo	[47]
R8	liposomes	Non-small cell lung	n vitro	[47]

		cancer cell line, A549		

5.3: Some Clinical Challenges of Cell Penetrating Peptides :

Due to their minimal cytotoxicity and exceptionally high transduction efficiency—the extent to which CPPs internalize into cellular membranes—CPPs have been the focus of a lot of research attention in recent decades. These peptide sequences have been identified to be an effective option for intracellular delivery due to their capacity to move across cellular membranes. The therapy of cancer is one appealing use for CPPs. When therapeutic drugs are delivered via CPPs, tumor cells may absorb them more readily and the effectiveness of the treatment may be enhanced. The identification of many CPPs in recent years has raised questions about the possibility of using peptides to carry drugs into cancerous cells.Through specific administration of drugs into tumors, CPPs can avoid many of the challenges associated with using conventional treatments to treat cancer. It should be emphasized that, in addition to their many benefits, CPPs have several drawbacks because of their functional and chemical characteristics.Cell, tissue, and organ specificity are limited in the many first generation CPPs.

The use of CPPs has improved the effectiveness of drug delivery.Toxicity, tissue transportation, cell specificity, dissolution and stability, immunogenicity, and endosomal degradation must all be evaluated to determine CPP pharmacokinetic properties. However, the mechanism of CPP internalization involves non-specific attachment to bilayer phospholipids on the cell membrane, which severely limits the therapeutic application of CPPs.

Additionally, animal model validation is required for the evaluation of immunological parameters and pharmacokinetic investigations of CPPs . The possibility of an undesirable immunological response may be raised by polypeptide CPPs . Also, cellular toxicity may result from the treatments' off-target absorption by any normal tissue .Conversely, endosomal degradation represents a disadvantage, and CPPs ought to be engineered with efficient endosomal escape to expedite carrier release[21]

5.4 : Modification strategies for Cell Penetrating peptides

Due to their functional and chemical characteristics, CPPs have several benefits, but it should be focused on that they also have numerous drawbacks.Low cell, tissue, and organ specificity are some major drawbacks of most of the CPPs.The absorption into intracellular endosomes is one of the main disadvantages of cpps .The stability and integrity of CPPs' physical and chemical composition are essential to their activity. Nevertheless, conventional CPPs have a brief half-life in vivo, mostly because of their decreased protease resistance and their incapacity of leaving the endosome. CPPs with increased stability and improved penetrating capability must be developed. Currently, there are several ways to overcome the drawbacks and limitations of CPPs.

Chemical Alteration : Proteases are primarily responsible for the degradation of CPPs. So if we chemically alter the CPPs it is possible to increase its stability. These alterations can include side-chain modifications, chiral changes, enzyme cleavage site alterations, terminal enhancements, and the use of artificial amino acids, by which Protease recognition can be prevented.

Changes in conformity: Conformational modifications, which includes backbone cyclization, disulphide bonding, and conformational freezing, are capable of protecting peptides from protease degradation and increase the stability of the structure of CPPs.

By increasing specificity : The tumor drug-targeted delivery system has to have two crucial abilities: high cell penetration and selective targeting capabilities. Improvement techniques have been presented by several studies to increase the specificity of CPPs. Certain techniques can enhance not just specificity but also other CPP flaws like endosome escape rate.

Activatable CPPs: Activatable CPPs (ACPPs) are one approach to address the issue of CPPs' lack of specificity . ACPPs are an entirely new family of potential molecular diagnostic probes for the detection of enzymatic processes and innovative in vivo targeting compounds . They are composed of a neutralizing polyanion and a cell-penetrating peptide (CPP) that ispolycataonic linked by a cleavable linker . This structure prevents electrostatic interactions, which in turn prevents absorption into cells, and decreases the total charge to almost zero. Additionally, as MMPs are linked to tumor illnesses and have been proven to express excessively in a variety of human tumor types, they are likely the most investigated CAPs for tumor-specific delivery of drugs. As such, the ACPP method may potentially be utilized to alter anticancer medications for tumor-targeting treatment.

CPPs with tumor-homing capabilities : The development of comparable tumour-orientating CPPs is the most straightforward method to enhance the cellular selectivity of CPPs. Oligopeptides with thirty or fewer amino acids that can attach to tumor cells both precisely and efficiently are known as tumor-homing CPPs. It may be used to create an entirely new non-invasive tumor imaging system for medical and therapeutic uses. Delivery by antibody combined CPPs: Numerous more homing chemicals exist in addition to those already mentioned, such as antibodies and ligands like peptides, oligonucleotides, sugars, or vitamins. By using either antigens or receptors on the surface of the tumor cells, they can be combined with CPP to accomplish selectivity in the targeting of tumor cells. These homing chemicals can also focus upon the drugs to be transported to tumor tissues, allowing for specific treatment. Delivery by -CPPs combined with ligand or receptor : The presence of several excessively expressed receptors and enzymes on the outside of tumor cells, in comparison to several further normal cells, is another indicator of the unique environment of tumor tissues and may also be employed for the targeted structure of CPP-based DDS. The folate receptor might be thought of as a potential therapeutic target area since it has been found in a number of malignancies, including mesothelioma, endometrial cancer, carcinoma of renal cell , adenocarcinoma of lung , and some breast cancers. Modification of the cytotoxicity and immunogenicity : CPPs may raise the chance of immunological responses, which may decrease the effectiveness of their medication and trigger an immunological response. While CPPs' immunogenicity in anti-

cancer therapy is flawed, several research have taken use of this trait and shown how useful it is for tumor immunotherapy.Consequently, altering CPP to antigens is a useful tactic to improve the effectiveness of nanovaccines in cancer immunotherapy.

Chapter 6: Conventional Chemotherapy Vs Advanced nanomedication for the treatment of Cancer by Cell penetrating peptides

Conventional chemotherapy still has several drawbacks and shortcomings even though having improvements in oncological research and treatment.One such is the standard medication drug doxorubicin, which has a weak tumor penetrance. Due to insufficient medication concentrations reaching the deeper layers of the tumor, cancer cells are able to multiply and keep undergoing mutations due to the inadequate penetration. The second problem is that tumors have high interstitial pressure, which prevents medications from being delivered efficiently by transcapillary transport.A further issue is the gradual development of tumor resistance to chemotherapy; this process is not fully understood, but it is believed to be facilitated by cancer stem cells and result in tumor relapses.Yet another issue is the gradual growth of tumor resistance to chemotherapy; this process is not fully understood, but it is believed to be facilitated by cancer stem cells and result in tumor relapses. One additional issue with contemporary cancer treatments is the requirement for high dosages because of the lack of targeted specificity, which greatly increases toxicity and adverse effects and makes chemotherapy difficult for patients to handle.The lack of targeted specificity in modern anticancer chemotherapy frequently leads to side effects as tiredness, weakness, nausea, sleeplessness, depression of the bone marrow, and many other negative consequences[36].

Chemotherapy, radiation, and surgery are the most often used cancer treatments. They are local therapies, but they also have a number of drawbacks and restrictions. For instance, early detection is necessary for surgery since it reduces the likelihood of metastatic development. Nevertheless, overdiagnosis has led to an increase in the annual number of mastectomies and prostatectomies performed.In 30–40% of solid tumor cases, radiotherapy is used either in isolation or in conjunction with other therapies. However, it has serious negative effects and damages healthy tissues and tumor cells genetically. Additionally, inflammation and oxidative damage are brought on by radiation exposure. Excessive dosages impair the tissue's capacity to mend by causing persistent harm. Chemotherapy is often non-specific, which causes cytotoxic damage to various parts of the body and resistance to growth. It has been demonstrated that radiation and chemotherapy induces double-strand breaks in DNA, which increases the production of reactive oxygen substances (ROS) and the overall

stress response. Along with apoptosis, this damage can cause arrest of cell cycle, the senescence mitotic catastrophe, an inflammatory response, and tissue fibrosis[25]. Additionally, a few limitations including low stability in vivo, shorter action times, and a lack of cell selectivity prevent the continued use of CPPs in the treatment of tumours.However, after conducting numerous studies, scientists and researchers have ultimately brought out some of the previously mentioned strategies(activable cpps, chemical alterations , conformational modifications , tumor homing cpps, increasing efficiency and selectivity , delivery with ligand/antibody - combined cpp and also cytotoxicity and immunogenicity modification) that have competently rectified the shortcomings of CPPs during in vitro experiments, with some of them yielding positive outcomes in pre-clinical animal models.So there is doubt that administration or employment of cell penetrating peptides for the therapy of cancer is more beneficial and potentialy effective than conventional chemotherapy .

6.1 : Mechanism of uptake of Cell Penetrating Peptides :

The fact that CPPs can deliver a variety of cargoes into cells is a well-established fact. But there are still a lot of disagreements about how cells take up the cargo. These disagreements arise mostly from differences in cell types (membrane lipid composition, for example), concentration, structure, and other characteristics of the transported cargo, as well as experimental conditions (pH and temperature). Despite the fact that the exact process of cellular absorption of CPPs is yet unknown, it is hypothesized that, based on the many physicochemical features of CPPs, there may be multiple separate mechanisms or numerous mechanisms in action. Typically, two types of cellular absorption routes are available for CPPs or CPP/cargoes based on whether energy is needed for internalization : Direct translocation and endocytosis.

Endocytosis-mediated pathway: There are many mechanisms involved in endocytosis, such as pinocytosis for solute absorption and phagocytosis for the uptake of big particles. There are three different types of pinocytosis: independent of clathrin and/or caveolin, reliant on the coat proteins, and macropinocytosis.The process of macropinocytosis is linked to the inward folding of the plasma membrane's outer layer, which produces vesicles known as macropinosomes. The membrane that envelops the resulting macropinosomes resembles the cell

membrane. Membrane invagination requires the dynamin protein.Clathrin or caveolin pits are involved in the uptake process in receptor-mediated endocytosis. The intracellular portion of the membrane is covered by the proteins caveolin and clathrin. They have to be present for membrane invagination and aid in the formation of vesicles following the binding of the extracellular chemical to the membrane receptor. Vesicles coated with clathrin have a diameter of a few hundred nanometers, but those coated with caveolin have a diameter of between 50 and 80 nm[29]

Direct Translocation : Direct translocation is a form of cellular absorption that happens independently of energy and is also called the nonendocytosis pathway or the mechanism that is energy dependent . The cationic CPPs' interactions with the anionic elements of the cell membrane, namely the phospholipid bilayer and heparan sulphate (HS), forms the basis of this process.Based on the variations in corresponding uptake methods, four models are suggested: the "carpet-like," "barrel-stave," "inverted micelle," and membrane-thinning models.One concept that has been proposed from the beginning for the direct penetration of penetratin is the "inverted micelle." This method also involves the contact of hydrophobic residues, like tryptophan, with the hydrophobic part of the membrane, along with the interaction of the positively charged CPP with the negatively charged components of the lipid membrane. For the CPPs that are highly cataonic like TAT, this mechanism is thus unlikely (48–60). The barrel stave model and the toroidal model are two models that describe pore development . According to the barrel stave model, hydrophobic residues are near to the lipid chains and hydrophilic residues create the core pore inside a barrel formed by helical CPPs. According to the toroidal model, lipids bend so that the CPP is constantly in close proximity to the headgroup, forming a pore with the CPP. When the peptide concentration exceeds a specific threshold, which varies depending on the specific peptide, holes manifest in both processes.The negatively charged phospholipid and cationic CPP interactions cause the membrane to carpet in the carpet-like model and thin in the membrane-thinning model, respectively. The CPP then translocates as a result.When the concentration of CPP is higher than a threshold, further translocation of the CPP occurs[29]



FIG 03 :Uptake mechanism of Cell penetrating peptides(Madani et al., 2011)

In order to improve the introduction of drugs into cells with minimal toxicity, cell penetrating peptides, or CPPs, have attracted special interest. In addition, CPPs have been used in a wide range of medical sectors, such as cancer therapy, enzyme replacement therapy, anti-inflammatory therapy employing antisense peptide nucleic

acids (PNAs), imaging and biosensing applications, and vaccine construction. The intracellular distribution of relevant drugs and drug carriers is facilitated by CPPs because they may transport a variety of cargo without causing cellular damage. The direct activities of cpps as antifungal, antiviral, and antiparasitic agents as well as their use as a drug delivery vehicle for small interfering RNA, nucleotides, tumor treatment, protein, and peptides are among the many diverse biological uses known to exist.

6.2 : Mechanism of Conventional Caancer treatment :

There are currently several methods of cancer therapy. The therapy options available to you will be determined by the type of cancer you have and its stage. Some patients with cancer will be given just one therapy. However, most patients usually recieves combination of therapies, including surgery, chemotherapy or radiation therapy. Patients might be given immunotherapy, targeted treatment, or hormone therapy[8]

Chemotherapy flows throughout the entire body via the bloodstream. Thus, it can cure cancer cells practically wherever they are in the body. Chemotherapy attacks cells that are breaking down into two new ones.Cells in cancer continue to divide until they form a solid mass which known as a tumor .Cancer cells multiply significantly more often than most normal cells, making chemotherapy considerably more likely to destroy them.Some medications destroy dividing cells by disrupting the regulatory center that causes the cell to divide. Additional drugs disrupt the chemical mechanisms involved in replication of cells. Genes are damaged by chemotherapy within the cell nucleus .Certain medications deteriorate cells during division. Some harm cells by copying all of their genes prior to splitting. Chemotherapy is much less probable to cause harm to dormant cells, such as the majority of normal ones[14].



FIG 04 : Mechanism of Chemotherapy

Hormone therapy is a form of cancer therapy that reduces or prevents the proliferation of cancer cells that rely on hormones for growth.Hormone therapy is carried out to treat cancers in prostate and breast cancers that rely on hormones for progression. Hormone therapy is most commonly combined with other therapies of cancer . The sort of therapy required depends on what type of cancer the patient has ,and how far it has spreaded , whether it requires any hormones to develop not , and whether any other health issuesis present or not[13]

Hormone therapy operates in a pair of primary methods either it prevents the release of aberrant hormones that can lead to cancer or modifies the functioning of hormones.Hormone based therapies may include the employment of artificial hormones or medicines to disturb the body's natural hormones. It inhibits the flow of hormones to the tissues that have been damaged , restricting the cancer of the resources itrequires to thrive.Some medications inhibit the synthesis of usual hormones completely. This also inhibits or delays the development of the malignancy[14]



FIG 05 : Mechanism of Hormone Therapy

Immunotherapy is another type of therapy for cancer that assists the body's immune system in treating cancer. The body's immune system defends the body against infections and other disorders .Immunotherapy is a sort of biological treatment that employs compounds derived from live creatures to combat cancer. Cancer immunotherapy aims to transfer the target from tumor cells to the patient's immune system, allowing for the mobilization and amplification of the anticancer immune response. This allows the immune cells to detect, attack , and then finally kill tumor cells[30]

Immunotherapies involve a variety of ways to fight tumor cells. Immunotherapy can be achieved by the following methods .Checkpoint inhibitors interrupt cancer cells' signals that deceive the immune system into believing they're healthy cells, exposing them to immune system attack.Cytokines are molecules of proteins that assist with controlling and directing the immune system. These are generated in a laboratory and then injected into the body in considerably greater quantities than they occur naturally.Cancer vaccines, that could decrease the risk of cancer by combating cancer-causing viruses or can treat tumours by activating the immune system to attack cancerous cells in a specific section of the body[17]



FIG 06 : Mechanism of Immunotherapy

Radiation therapy (commonly known as radiotherapy) is a form of cancer therapy that employs high levels of radiation to eliminate cancer cells and decrease tumors.The use of radiation at elevated levels eliminates or prevents the formation of cancer cells by damaging DNA. Cells from cancer that endured having their DNA damaged beyond repair stop proliferating and die. The body degrades and eliminates damaged cells as they die.Radiation therapy does not kill cancer cells instantly.It takes several days or weeks of treatment to generate enough DNA damage to kill cancer cells. Cancer cells go on dying for a few weeks or months afterwards after radiation therapy is completed[34]

Ultimately, it makes use of the high-frequency particulates or waves to target the DNA within cells in the body and affect their propensity to reproduce. Whenever the genetic material required for the replication and mitosis process is damaged, the cells are unable to replicate properly, and the growth of a malignant tumor is slowe[33]



FIG07 : Radiation Therapy

Chapter 7: Future Prospective and Scopes of Cell penetrating peptides

For cancer treatment, targeted administration using cell-targeting peptides (CTPs) that can identify cancer cells is very appealing. In a model system, the usage of these peptides has improved medication delivery's effectiveness and specificity while lowering adverse effects.

The primary obstacle to the clinical development of CPPs continues to be their lack of cell selectivity. Similarly, inadequate antitumor efficacy and insufficient selectivity towards tumor cells are the main problems with traditional treatment for cancer.But still cell penetrating peptides comparatively have more potential to treat cancer with less side effects.

Before introducing CPPs into clinical trials, several kinds of challenges must be addressed, including stabilization in vivo, its immunogenicity, cellular toxicity, lack for particular intracellular uptake, and failure to exit from endosomes. Cost, simplicity of synthesis, suitability for industrial manufacturing, and elimination should all be taken into account when evaluating therapeutic uses. These problems should be addressed by the implementation of CPPs in the future, and a number of novel CPP-based delivery methods should be assessed.

Overall, the effectiveness, safety, and final cost of the CPP-based method for clinical application determine its success.The development of a CPP-based delivery system that is safe, effective, easy to manufacture, affordable, and has a wide range of possible therapeutic applications is very promising. More precise techniques for the detection and treatment of diseases such tumors inflammation, illnesses of the neurological system, otoprotective, ophthalmic complications, and hyperglycemia may be possible using CPPs and CPP/cargo complexes. In addition, we are certain that over the course of the coming decades, CPP medications or CPP/cargo combinations will be readily accessible to consumptions[45]

Chapter 8 : Discussion and Conclusion

CPPs finally appear to be prepared for the move from lab bench to clinical applications, after several years of study. Because there are currently few clinically viable delivery methods and many treatments have significant side effects, the field of cancer therapy will probably be among the first to profit from the usage of CPPs. The first CPP systems to be used in clinical settings will probably be liposomal versions of common cancer chemotherapeutics.

Unfortunately because of its shortcomings, the FDA has not authorized any such therapy approach. Restriction on CPPs' application in anti-cancer therapy is also imposed by the absence of a more thorough understanding of them, including their cellular absorption processes.Clinical trial advancement is hampered by our lack of understanding of the morphological and external influences that impact their function in biological situations.

While the focus of current clinical trials is on drug efficiency, peptide medicines are more heavily influenced by conventional adsorption, distribution, metabolism, and excretion (ADME) pharmacokinetic concerns than small-sized pharmaceuticals. Upcoming clinical trials will primarily address timing, dosage, and delivery methods. For every target, an estimate of the necessary auxiliaries, the cytotoxicity of each cargo complexs of cell penetrating peptides , and the transport efficiency must be made.

Numerous preclinical and clinical research advancements were addressed in this review, highlighting the key benefits of CPPs as determining agents for tumor targeting and cellular internalization. Soon, CPPs may be more qualified for innovative anti-cancer pharmaceuticals but for that the shortcomings of the optimization approach and other issues need to be resolved in the future .

References :

1. Admin, & Admin. (2017, January 24). The role of immunotherapy in treating solid cancers | Cancer World Archive. Retrieved from https://archive.cancerworld.net/e-grandround/the-role-of-immunotherapy-in-treating-solid-cancers/
2. Bisoyi, P. (2022). Malignant tumors – as cancer. In *Elsevier eBooks* (pp. 21–36). https://doi.org/10.1016/b978-0-323-99883-3.00011-1
3. Bottens, R. A., & Yamada, T. (2022). Cell-Penetrating Peptides (CPPs) as Therapeutic and Diagnostic Agents for Cancer. *Cancers*, *14*(22), 5546. https://doi.org/10.3390/cancers14225546
4. Brown, J. S., Amend, S. R., Austin, R. H., Gatenby, R. A., Hammarlund, E. U., & Pienta, K. J. (2023). Updating the Definition of Cancer. *Molecular Cancer Research*, *21*(11), 1142–1147. https://doi.org/10.1158/1541-7786.mcr-23-0411
5. Cancer. (2024, September 30). Retrieved from https://my.clevelandclinic.org/health/diseases/12194-cancer
6. Carbone, A. (2020). Cancer Classification at the Crossroads. *Cancers*, *12*(4), 980. https://doi.org/10.3390/cancers12040980
7. Causes. (2017, September 12). Retrieved from https://stanfordhealthcare.org/medical-conditions/cancer/cancer/cancer-causes.html
8. Chemotherapy to Treat Cancer. (2022, August 23). Retrieved from https://www.cancer.gov/about-cancer/treatment/types/chemotherapy#how-chemotherapy-works-against%20cancer
9. Du, Y., Wang, L., Wang, W., Guo, T., Zhang, M., Zhang, P., . . . Fan, J. (2018). Novel Application of Cell Penetrating R11 Peptide for Diagnosis of Bladder Cancer. *Journal of Biomedical Nanotechnology*, *14*(1), 161–167. https://doi.org/10.1166/jbn.2018.2499
10. Gori, A., Lodigiani, G., Colombarolli, S. G., Bergamaschi, G., & Vitali, A. (2023a). Cell Penetrating Peptides: Classification, Mechanisms, Methods of Study, and Applications. *ChemMedChem*, *18*(17). https://doi.org/10.1002/cmdc.202300236
11. Healthdirect Australia. (n.d.). Chemotherapy. Retrieved from https://www.healthdirect.gov.au/chemotherapy

12. Hobbs, H. (2023, January 17). Cancer: Types, Causes, Prevention, and More. Retrieved from https://www.healthline.com/health/cancer#causes
13. Hormone Therapy for Cancer. (2022, August 23). Retrieved from https://www.cancer.gov/about-cancer/treatment/types/hormone-therapy#how-hormone-therapy-is-used-a%20gainst-cancer
14. How chemotherapy works. (n.d.). Retrieved from https://www.cancerresearchuk.org/about-cancer/treatment/chemotherapy/how-chemotherapy-works
15. How Hormone Therapy Works | UPMC Hillman Cancer Center. (n.d.). Retrieved from https://hillman.upmc.com/cancer-care/medical-oncology/hormone-therapy/how-does-hormone-therapy%20work
16. Huang, C., Li, Z., & Conti, P. S. (2011). In Vivo Near-Infrared Fluorescence Imaging of Integrin α2β1 in Prostate Cancer with Cell-Penetrating-Peptide–Conjugated DGEA Probe. *Journal of Nuclear Medicine*, *52*(12), 1979–1986. https://doi.org/10.2967/jnumed.111.091256
17. Immunotherapy for Cancer: What is It & How Do the Drugs Work. (n.d.). Retrieved from https://www.cancercenter.com/treatment-options/precision-medicine/immunotherapy#Q2
18. Javadzadeh, Y., & Bahari, L. A. (2017). Therapeutic Nanostructures for Dermal and Transdermal Drug Delivery. In *Elsevier eBooks* (pp. 131–146). https://doi.org/10.1016/b978-0-323-52727-9.00008-x
19. Kaewjanthong, P., Sooksai, S., Sasano, H., Hutvagner, G., Bajan, S., McGowan, E., & Boonyaratanakornkit, V. (2022). Cell-penetrating peptides containing the progesterone receptor polyproline domain inhibits EGF signaling and cell proliferation in lung cancer cells. *PLoS ONE*, *17*(3), e0264717. https://doi.org/10.1371/journal.pone.0264717
20. Khairkhah, N., Namvar, A., & Bolhassani, A. (2023a). Application of Cell Penetrating Peptides as a Promising Drug Carrier to Combat Viral Infections. *Molecular Biotechnology*, *65*(9), 1387–1402. https://doi.org/10.1007/s12033-023-00679-1
21. Khairkhah, N., Namvar, A., & Bolhassani, A. (2023b). Application of Cell Penetrating Peptides as a Promising Drug Carrier to Combat Viral Infections. *Molecular Biotechnology*, *65*(9), 1387–1402. https://doi.org/10.1007/s12033-023-00679-1

22. Kurrikoff, K., Aphkhazava, D., & Langel, Ü. (2019). The future of peptides in cancer treatment. *Current Opinion in Pharmacology*, *47*, 27–32. https://doi.org/10.1016/j.coph.2019.01.008

23. Li, L., Duns, G. J., Dessie, W., Cao, Z., Ji, X., & Luo, X. (2023). Recent advances in peptide-based therapeutic strategies for breast cancer treatment. *Frontiers in Pharmacology*, *14*. https://doi.org/10.3389/fphar.2023.1052301

24. Li, Y., Hao, L., Liu, F., Yin, L., Yan, S., Zhao, H., Sun, Y. (2019). Cell penetrating peptide-modified nanoparticles for tumor targeted imaging and synergistic effect of sonodynamic/HIFU therapy</p> *International Journal of Nanomedicine*, *Volume 14*, 5875–5894. https://doi.org/10.2147/ijn.s212184

25. Longoria-García, S., Sánchez-Domínguez, C. N., & Gallardo-Blanco, H. (2022). Recent applications of cell-penetrating peptide guidance of nanosystems in breast and prostate cancer (Review). *Oncology Letters*, *23*(3). https://doi.org/10.3892/ol.2022.13223

26. Lu, Z., Xiao, B., Chen, W., Tang, T., Zhuo, Q., & Chen, X. (2023). The potential of ferroptosis combined with radiotherapy in cancer treatment. *Frontiers in Oncology*, *13*. https://doi.org/10.3389/fonc.2023.1085581

27. Lulla, R. R., Goldman, S., Yamada, T., Beattie, C. W., Bressler, L., Pacini, M., Fouladi, M. (2016). Phase I trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study. *Neuro-Oncology*, *18*(9), 1319–1325. https://doi.org/10.1093/neuonc/now047

28. Lung Cancer Statistics | How Common is Lung Cancer? (n.d.). Retrieved from https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics

29. Madani, F., Lindberg, S., Langel, Ü., Futaki, S., & Gräslund, A. (2011). Mechanisms of Cellular Uptake of Cell-Penetrating Peptides. *Journal of Biophysics*, *2011*, 1–10. https://doi.org/10.1155/2011/414729

30. Mahmood, A., & Srivastava, R. (2022). Etiology of cancer. In *Elsevier eBooks* (pp. 37–62). https://doi.org/10.1016/b978-0-323-99883-3.00008-1

31. Malkas, L. H., Herbert, B. S., Abdel-Aziz, W., Dobrolecki, L. E., Liu, Y., Agarwal, B., Hickey, R. J. (2006). A cancer-associated PCNA expressed in breast cancer has implications as a potential biomarker.

Proceedings of the National Academy of Sciences, *103*(51), 19472–19477. https://doi.org/10.1073/pnas.0604614103

32. Nasir, A. (2020, February 12). Classification of Cancer. Retrieved from https://www.linkedin.com/pulse/classification-cancer-amjad-nasir
33. News-Medical. (2021, February 3). Radiation therapy mechanism. Retrieved from https://www.news-medical.net/health/Radiation-Therapy-Mechanism.aspx
34. Radiation Therapy for Cancer. (2019, January 8). Retrieved from https://www.cancer.gov/about-cancer/treatment/types/radiation-therapy#HRTWAC
35. Roser, M., & Ritchie, H. (2024, March 12). Cancer. Retrieved from https://ourworldindata.org/cancer
36. Stiltner, J., McCandless, K., & Zahid, M. (2021a). Cell-Penetrating Peptides: Applications in Tumor Diagnosis and Therapeutics. *Pharmaceutics*, *13*(6), 890. https://doi.org/10.3390/pharmaceutics13060890
37. Understanding Cancer -- the Basics. (2024, July 2). Retrieved from https://www.webmd.com/cancer/understanding-cancer-basics
38. Vale, N., Duarte, D., Silva, S., Correia, A. S., Costa, B., Gouveia, M. J., & Ferreira, A. (2020a). Cell-penetrating peptides in oncologic pharmacotherapy: A review. *Pharmacological Research*, *162*, 105231. https://doi.org/10.1016/j.phrs.2020.105231
39. Vale, N., Duarte, D., Silva, S., Correia, A. S., Costa, B., Gouveia, M. J., & Ferreira, A. (2020b). Cell-penetrating peptides in oncologic pharmacotherapy: A review. *Pharmacological Research*, *162*, 105231. https://doi.org/10.1016/j.phrs.2020.105231
40. WCRF International. (2024, June 26). Breast cancer statistics | World Cancer Research Fund International. Retrieved from https://www.wcrf.org/cancer-trends/breast-cancer-statistics/
41. What Is Cancer? (2021, October 11). Retrieved from https://www.cancer.gov/about-cancer/understanding/what-is-cancer#types
42. World Health Organization: WHO. (2022, February 3. Cancer. Retrieved from https://www.who.int/news-room/fact-sheets/detail/cancer

43. World Health Organization: WHO. (2024, March 5). Cervical cancer. Retrieved from https://www.who.int/news-room/fact-sheets/detail/cervical-cancer

44. World Health Organization: WHO & World Health Organization: WHO. (2023, July 11). Colorectal cancer. Retrieved from https://www.who.int/news-room/fact-sheets/detail/colorectal-cancer

45. Xie, J., Bi, Y., Zhang, H., Dong, S., Teng, L., Lee, R. J., & Yang, Z. (2020). Cell-Penetrating Peptides in Diagnosis and Treatment of Human Diseases: From Preclinical Research to Clinical Application. *Frontiers in Pharmacology*, *11*. https://doi.org/10.3389/fphar.2020.00697

46. Zhang, T., Wu, K., Ding, C., Sun, K., Guan, Z., Wang, X.. Fan, J. (2015). Inhibiting bladder tumor growth with a cell penetrating R11 peptide derived from the p53 C-terminus. *Oncotarget*, *6*(35), 37782–37791. https://doi.org/10.18632/oncotarget.5622

47. Zhou, M., Zou, X., Cheng, K., Zhong, S., Su, Y., Wu, T.Jiang, Y. (2022a). The role of cell-penetrating peptides in potential anti-cancer therapy. *Clinical and Translational Medicine*, *12*(5). https://doi.org/10.1002/ctm2.822